Kisqali Femara Co-Pack (ribociclib/letrozole) — United Healthcare
Recurrent or metastatic endometrial carcinoma
Initial criteria
- Diagnosis of recurrent or metastatic endometrial cancer
- AND Tumor is estrogen receptor (ER)-positive
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Kisqali Femara Co-Pack therapy
Approval duration
12 months